AI enabled discovery PsychoGenics combines AI-enabled phenotypic drug discovery with preclinical CNS models, presenting a compelling value proposition for biopharma partners seeking to accelerate early-stage screening and reduce late-stage attrition.

Neuro disease focus Specialized portfolio of validated mouse models for Alzheimer’s, Huntington’s, Parkinson’s, autism, schizophrenia, SMA, muscular dystrophy and pain positions PsychoGenics as a go-to CRO for CNS and orphan disorder programs requiring translational endpoints.

Strategic partnerships Recent collaborations with Sunovion and Carnegie Mellon emphasize capabilities in AI-driven behavioral analysis and platform integration, signaling openness to co-development and technology licensing deals.

Clinical readiness Extensive translational testing capabilities including behavioral testing, translational EEG, histology and microdialysis enable clients to quantify efficacy early, potentially shortening timelines to Investigational New Drug applications.

Growth indicators SBIR financing and a recent corporate brand refresh suggest ongoing growth and market validation, creating opportunities for additional grant-aligned projects, clinical translation services, or expanded research collaborations.